Impact on in-hospital mortality of ceftaroline versus standard of care in community-acquired pneumonia: a propensity-matched analysis.
Antimicrobials
Ceftaroline
Community-acquired pneumonia
Pneumonia
Severe pneumonia
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
18
08
2021
accepted:
04
11
2021
pubmed:
13
11
2021
medline:
1
2
2022
entrez:
12
11
2021
Statut:
ppublish
Résumé
The purpose of this study is to evaluate the in-hospital mortality of community-acquired pneumonia (CAP) treated with ceftaroline in comparison with standard therapy. This was a retrospective observational study in two centers. Hospitalized patients with CAP were grouped according to the empiric regimen (ceftaroline versus standard therapy) and analyzed using a propensity score matching (PSM) method to reduce confounding factors. Out of the 6981 patients enrolled, 5640 met the inclusion criteria, and 89 of these received ceftaroline. After PSM, 78 patients were considered in the ceftaroline group (cases) and 78 in the standard group (controls). Ceftaroline was mainly prescribed in cases with severe pneumonia (67% vs. 56%, p = 0.215) with high suspicion of Staphylococcus aureus infection (9% vs. 0%, p = 0.026). Cases had a longer length of hospital stay (13 days vs. 10 days, p = 0.007), while an increased risk of in-hospital mortality was observed in the control group compared to the case group (13% vs. 21%, HR 0.41; 95% CI 0.18 to 0.62, p = 0.003). The empiric use of ceftaroline in hospitalized patients with severe CAP was associated with a decreased risk of in-hospital mortality.
Identifiants
pubmed: 34767120
doi: 10.1007/s10096-021-04378-0
pii: 10.1007/s10096-021-04378-0
pmc: PMC8588767
doi:
Substances chimiques
Anti-Bacterial Agents
0
Cephalosporins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
271-279Subventions
Organisme : CIBERES
ID : CIBERES CB06/06/0028
Informations de copyright
© 2021. The Author(s).
Références
Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K et al (2019) Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 200:e45-67. https://doi.org/10.1164/rccm.201908-1581ST
doi: 10.1164/rccm.201908-1581ST
pubmed: 31573350
pmcid: 6812437
Cillóniz C, Dominedò C, Garcia-Vidal C, Torres A (2018) Community-acquired pneumonia as an emergency condition. Curr Opin Crit Care 24:531–539. https://doi.org/10.1097/MCC.0000000000000550
doi: 10.1097/MCC.0000000000000550
pubmed: 30239410
Ferrer M, Travierso C, Cilloniz C, Gabarrus A, Ranzani OT, Polverino E et al (2018) Severe community-acquired pneumonia: characteristics and prognostic factors in ventilated and non-ventilated patients. PLoS ONE 13:e0191721. https://doi.org/10.1371/journal.pone.0191721
doi: 10.1371/journal.pone.0191721
pubmed: 29370285
pmcid: 5784994
Waterer G (2018) Empiric antibiotics for community-acquired pneumonia: a macrolide and a beta-lactam please! Respirology 23:450–451. https://doi.org/10.1111/resp.13248
doi: 10.1111/resp.13248
pubmed: 29278281
Severiche-Bueno D, Parra-Tanoux D, Reyes LF, Waterer GW (2019) Hot topics and current controversies in community-acquired pneumonia. Breathe (Sheff) 15:216–225. https://doi.org/10.1183/20734735.0205-2019
doi: 10.1183/20734735.0205-2019
Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M et al (2021) Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect 27:83–88. https://doi.org/10.1016/j.cmi.2020.07.041
doi: 10.1016/j.cmi.2020.07.041
pubmed: 32745596
Cilloniz C, Dominedò C, Gabarrús A, Garcia-Vidal C, Becerril J, Tovar D et al (2021) Methicillin-susceptible staphylococcus aureus in community-acquired pneumonia: risk factors and outcomes. J Infect 82:76–83. https://doi.org/10.1016/j.jinf.2020.10.032
doi: 10.1016/j.jinf.2020.10.032
pubmed: 33144192
Cillóniz C, Dominedò C, Torres A (2019) Multidrug resistant gram-negative bacteria in community-acquired pneumonia. Crit Care 9(23):79. https://doi.org/10.1186/s13054-019-2371-3
doi: 10.1186/s13054-019-2371-3
Suaya JA, Mendes RE, Sings HL, Arguedas A, Reinert R-R, Jodar L et al (2020) Streptococcus pneumoniae serotype distribution and antimicrobial nonsusceptibility trends among adults with pneumonia in the United States, 2009–2017. J Infect 81:557–566. https://doi.org/10.1016/j.jinf.2020.07.035
doi: 10.1016/j.jinf.2020.07.035
pubmed: 32739491
File TM, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J et al (2010) Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 15(51):1395–1405. https://doi.org/10.1086/657313
doi: 10.1086/657313
Poon H, Chang MH, Fung HB (2012) Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Ther 34:743–765. https://doi.org/10.1016/j.clinthera.2012.02.025
doi: 10.1016/j.clinthera.2012.02.025
pubmed: 22444785
Eljaaly K, Wali H, Basilim A, Alharbi A, Asfour HZ (2019) Clinical cure with ceftriaxone versus ceftaroline or ceftobiprole in the treatment of Staphylococcal pneumonia: a systematic review and meta-analysis. Int J Antimicrob Agents 54(2):149–153. https://doi.org/10.1016/j.ijantimicag.2019.05.023
Polverino E, Dambrava P, Cillóniz C, Balasso V, Marcos MA, Esquinas C et al (2010) Nursing home-acquired pneumonia: a 10 year single-centre experience. Thorax 65:354–359. https://doi.org/10.1136/thx.2009.124776
doi: 10.1136/thx.2009.124776
pubmed: 20388763
Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC et al (2007) Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 1(44 Suppl 2):S27-72. https://doi.org/10.1086/511159
doi: 10.1086/511159
Cillóniz C, Ewig S, Polverino E, Marcos MA, Esquinas C, Gabarrús A et al (2011) Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 66:340–346. https://doi.org/10.1136/thx.2010.143982
doi: 10.1136/thx.2010.143982
pubmed: 21257985
Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stürmer T (2006) Variable selection for propensity score models. Am J Epidemiol 15(163):1149–1156. https://doi.org/10.1093/aje/kwj149
doi: 10.1093/aje/kwj149
Welte T, Kantecki M, Stone GG, Hammond J (2019) Ceftaroline fosamil as a potential treatment option for Staphylococcus aureus community-acquired pneumonia in adults. Int J Antimicrob Agents 54:410–422. https://doi.org/10.1016/j.ijantimicag.2019.08.012
doi: 10.1016/j.ijantimicag.2019.08.012
pubmed: 31404620
Blyth CC, Webb SAR, Kok J, Dwyer DE, van Hal SJ, Foo H et al (2013) The impact of bacterial and viral co-infection in severe influenza. Influenza Other Respir Viruses 7:168–176. https://doi.org/10.1111/j.1750-2659.2012.00360.x
doi: 10.1111/j.1750-2659.2012.00360.x
pubmed: 22487223
Bai B, Wang H, Li M, Ma X, Zheng J, Deng Q et al (2020) Two cases of influenza B virus-related fatal fulminant pneumonia complicated with Staphylococcus aureus infection in China diagnosed using next-generation sequencing (2018). Front Public Health 8:121. https://doi.org/10.3389/fpubh.2020.00121
doi: 10.3389/fpubh.2020.00121
pubmed: 32351925
pmcid: 7175880
Joynt GM, Lipman J, Gomersall CD, Young RJ, Wong EL, Gin T (2001) The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother 47:421–429. https://doi.org/10.1093/jac/47.4.421
doi: 10.1093/jac/47.4.421
pubmed: 11266414
Croisier-Bertin D, Hayez D, Da Silva S, Labrousse D, Biek D, Badiou C et al (2014) In vivo efficacy of ceftaroline fosamil in a methicillin-resistant Panton-Valentine leukocidin-producing Staphylococcus aureus rabbit pneumonia model. Antimicrob Agents Chemother 58:1855–1861. https://doi.org/10.1128/AAC.01707-13
doi: 10.1128/AAC.01707-13
pubmed: 24395236
pmcid: 4023709
Zhong NS, Sun T, Zhuo C, D’Souza G, Lee SH, Lan NH et al (2015) Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial. Lancet Infect Dis 15:161–171. https://doi.org/10.1016/S1473-3099(14)71018-7
doi: 10.1016/S1473-3099(14)71018-7
pubmed: 25539586
File TM, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J et al (2011) FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 66:iii19-32. https://doi.org/10.1093/jac/dkr096
doi: 10.1093/jac/dkr096
pubmed: 21482566
Low DE, File TM, Eckburg PB, Talbot GH, David Friedland H, Lee J et al (2011) FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 66(Suppl 3):iii33-44. https://doi.org/10.1093/jac/dkr097
doi: 10.1093/jac/dkr097
pubmed: 21482568
Taboada M, Melnick D, Iaconis JP, Sun F, Zhong NS, File TM et al (2016) Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials. J Antimicrob Chemother 71:1748–1749. https://doi.org/10.1093/jac/dkw136
doi: 10.1093/jac/dkw136
pubmed: 27076104
Ramirez JA, Wiemken TL, Peyrani P, Arnold FW, Kelley R, Mattingly WA et al (2017) Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis 13(65):1806–1812. https://doi.org/10.1093/cid/cix647
doi: 10.1093/cid/cix647
Cillóniz C, Polverino E, Ewig S, Aliberti S, Gabarrús A, Menéndez R et al (2013) Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. Chest 144:999–1007. https://doi.org/10.1378/chest.13-0062
doi: 10.1378/chest.13-0062
pubmed: 23670047
Lee JH, Kim HJ, Kim YH (2017) Is β-lactam plus macrolide more effective than β-lactam plus fluoroquinolone among patients with severe community-acquired pneumonia?: a systemic review and meta-analysis. J Korean Med Sci 32:77–84. https://doi.org/10.3346/jkms.2017.32.1.77
doi: 10.3346/jkms.2017.32.1.77
pubmed: 27914135
Gilbert TT, Arfstrom RJ, Mihalovic SW, Dababneh AS, Varatharaj Palraj BR, Dierkhising RA et al (2020) Effect of β-lactam plus macrolide versus fluoroquinolone on 30-day readmissions for community-acquired pneumonia. Am J Ther 27:e177–e182. https://doi.org/10.1097/MJT.0000000000000788
doi: 10.1097/MJT.0000000000000788
pubmed: 30418221
Postma DF, van Werkhoven CH, van Elden LJR, Thijsen SFT, Hoepelman AIM, Kluytmans JAJW et al (2015) Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 2(372):1312–1323. https://doi.org/10.1056/NEJMoa1406330
doi: 10.1056/NEJMoa1406330
Murphy DM, Forrest IA, Curran D, Ward C (2010) Macrolide antibiotics and the airway: antibiotic or non-antibiotic effects? Expert Opin Investig Drugs 19:401–414. https://doi.org/10.1517/13543781003636480
doi: 10.1517/13543781003636480
pubmed: 20151856
Stahlmann R, Lode H (2010) Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging 1(27):193–209. https://doi.org/10.2165/11531490-000000000-00000
doi: 10.2165/11531490-000000000-00000
Vouga Ribeiro N, Gouveia Melo R, Guerra NC, Nobre Â, Fernandes RM, Pedro LM et al (2020) Fluoroquinolones are associated with increased risk of aortic aneurysm or dissection: systematic review and meta-analysis. Semin Thorac Cardiovasc Surg 9(20):30404–30414. https://doi.org/10.1053/j.semtcvs.2020.11.011
doi: 10.1053/j.semtcvs.2020.11.011